CD48 is a novel immune checkpoint on tumour‐associated macrophages in hepatocellular carcinoma
CD48 represents a novel immune checkpoint on TAMs critical for HCC progression and immunotherapy resistance. Targeting CD48 may overcome immunosuppression and increase therapeutic efficacy in HCC.
Authors
- S. Wang
- Zhaozhao Li
- Weina Li (ORCID: https://orcid.org/0000-0002-8887-9261)
- Yueyuan Zhou (ORCID: https://orcid.org/0000-0002-3765-2585)
- Lei He (ORCID: https://orcid.org/0000-0001-5929-8129)
- G. Li
- Yueyuan Qiu
- Fei Xie (ORCID: https://orcid.org/0000-0003-0088-5905)
- Jieyu Zhang (ORCID: https://orcid.org/0000-0003-0492-9514)
- Man Li (ORCID: https://orcid.org/0000-0002-4035-5266)
- Haichen Du
- Yang Xiao (ORCID: https://orcid.org/0009-0008-3944-916X)
- Zhaowei Wang
- Yuan Gao
- Yingqi Zhang
- Xiaoying Lei
- Wangqian Zhang
- Gege Shi
- Haiyan Cao
- Duo Yu
- Kuo Zhang
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Gut
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1136/gutjnl-2025-336744
- Citations
- 1
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 24.43